Dynamics, outcomes and prerequisites of the first SARS-CoV-2 superspreading event in Germany in February 2020: a cross-sectional epidemiological study.


Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
06 04 2022
Historique:
entrez: 7 4 2022
pubmed: 8 4 2022
medline: 9 4 2022
Statut: epublish

Résumé

The first German SARS-CoV-2 outbreak was a superspreading event in Gangelt, North Rhine-Westphalia, during indoor carnival festivities called 'Kappensitzung' (15 February 2020). We determined SARS-CoV-2 RT-PCR positivity rate, SARS-CoV-2-specific antibodies, and analysed the conditions and dynamics of superspreading, including ventilation, setting dimensions, distance from infected persons and behavioural patterns. In a cross-sectional epidemiological study (51 days postevent), participants were asked to give blood, pharyngeal swabs and complete self-administered questionnaires. The SARS-CoV-2 superspreading event took place during festivities in the small community of Gangelt in February 2020. This 5-hour event included 450 people (6-79 years of age) in a building of 27 m × 13.20 m × 4.20 m. Out of 450 event participants, 411 volunteered to participate in this study. Primary outcome: infection status (determined by IgG ELISA). symptoms (determined by questionnaire). Overall, 46% (n=186/404) of participants had been infected, and their spatial distribution was associated with proximity to the ventilation system (OR 1.39, 95% CI 0.86 to 2.25). Risk of infection was highly associated with age: children (OR 0.33, 95% CI 0.267 to 0.414) and young adults (age 18-25 years) had a lower risk of infection than older participants (average risk increase of 28% per 10 years). Behavioural differences were also risk associated including time spent outside (OR 0.55, (95% CI 0.33 to 0.91) or smoking (OR 0.32, 95% CI 0.124 to 0.81). Our findings underline the importance of proper indoor ventilation for future events. Lower susceptibility of children/young adults indicates their limited involvement in superspreading.

Identifiants

pubmed: 35387836
pii: bmjopen-2021-059809
doi: 10.1136/bmjopen-2021-059809
pmc: PMC8987213
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e059809

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

Sci Total Environ. 2020 Aug 1;728:138882
pubmed: 32335410
Med Hypotheses. 2022 Jan;158:110741
pubmed: 34924680
J Glob Health. 2020 Dec;10(2):021101
pubmed: 33312511
Wellcome Open Res. 2020 May 1;5:83
pubmed: 32656368
Eur J Clin Microbiol Infect Dis. 2020 Nov;39(11):2005-2011
pubmed: 32638221
JAMA Pediatr. 2021 Feb 1;175(2):143-156
pubmed: 32975552
Nicotine Tob Res. 2021 Aug 4;23(8):1398-1404
pubmed: 33420786
EMBO Mol Med. 2020 Dec 7;12(12):e13296
pubmed: 33012091
Tob Induc Dis. 2020 Mar 20;18:20
pubmed: 32206052
Med Sci Monit. 2020 May 28;26:e926016
pubmed: 32463026
Int J Infect Dis. 2020 Nov;100:476-482
pubmed: 32949774
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Sci Rep. 2020 Jul 29;10(1):12732
pubmed: 32728118
Tob Induc Dis. 2020 Jul 03;18:58
pubmed: 32641924
Emerg Infect Dis. 2004 Feb;10(2):256-60
pubmed: 15030693
J Infect Dis. 2013 Mar 15;207(6):990-8
pubmed: 23264672
Nature. 2005 Nov 17;438(7066):355-9
pubmed: 16292310
Arch Acad Emerg Med. 2020 Sep 21;8(1):e74
pubmed: 33134970
Epidemiol Health. 2020;42:e2020049
pubmed: 32660218
PLoS One. 2021 Jun 10;16(6):e0242456
pubmed: 34111143
J Glob Health. 2020 Jun;10(1):011101
pubmed: 32612817
JAMA Netw Open. 2020 Dec 1;3(12):e2031756
pubmed: 33315116
C R Biol. 2020 Jun 05;343(1):33-39
pubmed: 32720486
Nat Commun. 2020 Nov 17;11(1):5829
pubmed: 33203887
Environ Toxicol Pharmacol. 2020 Aug;78:103411
pubmed: 32422280

Auteurs

Lukas Wessendorf (L)

Institute of Virology, University Hospital Bonn, Bonn, Germany.

Enrico Richter (E)

Institute of Virology, University Hospital Bonn, Bonn, Germany.

Bianca Schulte (B)

Institute of Virology, University Hospital Bonn, Bonn, Germany.

Ricarda Maria Schmithausen (RM)

Department of Hygiene, University Hospital Bonn, Bonn, Germany.

Martin Exner (M)

Department of Hygiene, University Hospital Bonn, Bonn, Germany.

Nils Lehmann (N)

Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Duisburg, Germany.

Martin Coenen (M)

Clinical Study Core Unit, Study Center Bonn (SZB), Rheinische Friedrich Wilhelms Universitat Bonn, Bonn, Germany.

Christine Fuhrmann (C)

Clinical Study Core Unit, Study Center Bonn (SZB), Rheinische Friedrich Wilhelms Universitat Bonn, Bonn, Germany.

Angelika Kellings (A)

Clinical Study Core Unit, Study Center Bonn (SZB), Rheinische Friedrich Wilhelms Universitat Bonn, Bonn, Germany.

Anika Hüsing (A)

Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Duisburg, Germany.

Karl-Heinz Jöckel (KH)

Institute for Medical Informatics, Biometry and Epidemiology, University of Duisburg-Essen, Duisburg, Germany.

Hendrik Streeck (H)

Institute of Virology, University Hospital Bonn, Bonn, Germany Streeck@ukbonn.de.
German Centre for Infection Research, Braunschweig, Niedersachsen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH